Iboga and Ibogaine: What They Are, Addiction Research, Cardiac Risks and Legal Status Around the World

Iboga and ibogaine are often discussed together, but they are not the same thing. Iboga is a plant, Tabernanthe iboga, native to Central Africa and deeply connected with traditional and spiritual practices, especially in Gabon and surrounding regions. Ibogaine is one of the plant’s psychoactive alkaloids and has attracted international attention because of possible effects on substance dependence.

What is ibogaine?

Ibogaine is sometimes described as an atypical psychedelic or oneirogen because it can produce prolonged dream-like, autobiographical and visionary experiences. Its pharmacology is complex and differs from classic serotonergic psychedelics such as psilocybin or LSD. Research has focused especially on opioid withdrawal, craving and addiction, although evidence remains much less developed than for established treatments for opioid use disorder.

Why addiction researchers became interested

Observational and early clinical studies have reported reductions in opioid withdrawal symptoms and craving after ibogaine. These findings are the reason the compound continues to attract scientific interest. But open-label or observational results cannot tell us with confidence how ibogaine compares with evidence-based treatments such as opioid agonist therapy, and they do not establish long-term effectiveness.

The cardiac risk is a central issue

Ibogaine has a safety profile that requires particular caution. A clinical observational study in people undergoing opioid detoxification found clinically important QTc prolongation, bradycardia and severe ataxia. In that small study, half of the participants reached a QTc interval above 500 milliseconds during monitoring. Ibogaine has also been associated with fatal cardiac arrhythmias in published literature. This is one reason unscreened or poorly monitored use can be dangerous.

What about newer mental-health research?

A 2024 prospective observational study reported improvements in functioning, PTSD, depression and anxiety among 30 male Special Operations veterans with traumatic brain injury who received magnesium-ibogaine together with complementary treatment modalities. The authors were clear that controlled clinical trials are needed. A 2026 follow-up analysis examined mystical experiences and PTSD outcomes in the same cohort. These results are intriguing, but they are not proof of efficacy for the general population.

Canada: prescription status does not mean approved treatment

Health Canada added ibogaine, including its salts, derivatives and analogues, to the Prescription Drug List in 2017 because of serious safety concerns. Health Canada has also stated that no health products containing ibogaine have been authorized for use in Canada and has reported serious and fatal adverse reactions associated with its use. The key distinction is important: being classified as a prescription drug is not the same as having an approved ibogaine medicine on the Canadian market.

United States: Schedule I

Under U.S. federal law, ibogaine is a Schedule I controlled substance. Current DEA controlled-substance materials list ibogaine under Schedule I. That means ordinary possession and clinical use are not legally available outside authorized research or other federal permissions.

New Zealand: classified as a prescription medicine

New Zealand takes a different regulatory approach. Medsafe’s medicines framework classifies ibogaine as a prescription medicine. This means it is not a freely available wellness product; supply and clinical use fall under medicine and prescribing rules. The classification reflects both possible therapeutic interest and significant safety concerns.

Brazil: not scheduled is not the same as approved

Brazil illustrates another legal nuance. ANVISA has stated that ibogaine is not on its controlled-substance lists, but commercial sale of ibogaine products is not authorized because there is no registered medicine containing the substance. Importation for research can occur through regulatory pathways. Again, “not scheduled as a controlled drug” should not be translated into “approved treatment.”

Respect for traditional iboga knowledge

Modern ibogaine clinics should not erase the cultural history of iboga. Iboga has longstanding ceremonial significance in Central African traditions, including Bwiti communities. Scientific interest in an isolated alkaloid is different from the cultural and spiritual knowledge surrounding the plant itself. Ethical discussion should include cultural respect, sustainability and benefit-sharing.

The responsible conclusion

Ibogaine may eventually contribute useful knowledge to addiction and mental-health treatment, but its cardiac risks and limited controlled evidence make casual self-treatment particularly concerning. The scientific question is not simply whether a powerful experience can occur. It is whether benefits can be demonstrated under conditions that reliably protect people from preventable harm.

Sources checked

Health Canada safety communication and Prescription Drug List; U.S. Drug Enforcement Administration controlled-substance schedules; New Zealand Medsafe classification materials; Brazil ANVISA; Clinical Addiction research on ibogaine cardiac safety; Cherian et al., Nature Medicine, 2024; 2026 Journal of Affective Disorders follow-up. Educational information only; not medical or legal advice.